Lucosky Brookman LLP congratulates its client, BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) on its successful closing of an underwritten public offering of 4,144,068 American Depositary Shares (“ADSs”) at a public offering price of $2.36 per ADS for gross proceeds to the Company of approximately $9.8 million. BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.
